Humira's Inevitable Decline: What's Waiting In The Wings?
Executive Summary
There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.
You may also be interested in...
Humira Biosimilar Interchangeability: The Race Begins
Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.
Humira Biosimilar Interchangeability: The Race Begins
Boehringer Ingelheim announcement is first public disclosure of interchangeability trial since US FDA draft guidance was released.
Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?
Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.